ArticleNature communications2023
Skin basal cell carcinomas assemble a pro-tumorigenic spatially organized and self-propagating Trem2+ myeloid niche.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 27 citations in OpenAlex.
- Diabetes-induced TREM2-endothelial cell signaling impairs ischemic vascular repair.Science translational medicine · 2026Article
- Decoding TREM2 Signaling Pathways: Linking Macrophage Glycolysis to Inflammatory Diseases in the CNS.Neurology(R) neuroimmunology & neuroinflammation · 2026Review
- Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity.Molecular oncology · 2026Article
- TREM2 as a central hub of neuroimmune-metabolic crosstalk in central nervous system disorders: from microglial biology to therapeutic targeting.Frontiers in immunology · 2026Review
- TREM2-mediated regulation of myeloid cells in the tumor microenvironment: new insights and therapeutic prospects.NPJ precision oncology · 2025Review
- TREM2 and LAG-3 in cancer and Alzheimer's disease immunotherapy.Trends in pharmacological sciences · 2025Review
- The spatial and single-cell landscape of skin: Charting the multiscale regulation of skin immune function.Seminars in immunology · 2025Review
- Acute TREM2 inhibition depletes MAFB-high microglia and hinders remyelination.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Wound localization and housing conditions dictate repair dynamics and scar formation.Lab animal · 2025Article
- Epithelial cell diversity and immune remodeling in bladder cancer progression: insights from single-cell transcriptomics.Journal of translational medicine · 2025Article
- Targeting immune checkpoints on myeloid cells: current status and future directions.Cancer immunology, immunotherapy : CII · 2025Review
- From Cancer to Immune Organoids: Innovative Preclinical Models to Dissect the Crosstalk between Cancer Cells and the Tumor Microenvironment.International journal of molecular sciences · 2024Review
- Basal-to-inflammatory transition and tumor resistance via crosstalk with a pro-inflammatory stromal niche.Nature communications · 2024Article
- Spatial landscapes of cancers: insights and opportunities.Nature reviews. Clinical oncology · 2024Review
- Contribution of Keratinocytes in Skin Cancer Initiation and Progression.International journal of molecular sciences · 2024Review
- Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment.Nature reviews. Cancer · 2024Review
- Tunable PhenoCycler imaging of the murine pre-clinical tumour microenvironments.Cell & bioscience · 2024Article
- Signaling Pathway Alterations Driven by BRCA1 and BRCA2 Germline Mutations are Sufficient to Initiate Breast Tumorigenesis by the PIK3CAH1047R Oncogene.Cancer research communications · 2024Article
- Unraveling the landscape of non-melanoma skin cancer through single-cell RNA sequencing technology.Frontiers in oncology · 2024Review
- Mechanisms of TREM2 mediated immunosuppression and regulation of cancer progression.Frontiers in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Daniel HaenselProgram in Epithelial Biology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-5168-4068
Bence DanielDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-2410-8767
Sadhana GaddamProgram in Epithelial Biology, Stanford University School of Medicine, Stanford, CA, USA.
Cory PanProgram in Epithelial Biology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-1808-6239
Tania FaboProgram in Epithelial Biology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-8987-0672
Jeremy BjelajacProgram in Epithelial Biology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-7628-1652
Anna R JussilaProgram in Epithelial Biology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-5451-1813
Fernanda GonzalezProgram in Epithelial Biology, Stanford University School of Medicine, Stanford, CA, USA.
Nancy Yanzhe LiProgram in Epithelial Biology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-6217-5234
Yun ChenDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
JinChao HouDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Tiffany PatelProgram in Epithelial Biology, Stanford University School of Medicine, Stanford, CA, USA.
Sumaira AasiDepartment of Dermatology, Stanford University School of Medicine, Stanford, CA, USA.
Ansuman T SatpathyDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-5167-537X
Anthony E OroProgram in Epithelial Biology, Stanford University School of Medicine, Stanford, CA, USA. oro@stanford.edu.ORCID 0000-0002-6261-138X
Stanford University · USGladstone Institutes · USWashington University in St. Louis · USStanford Medicine · US
Funding
Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Vittorio Sebastiano · 2007 to 2026
$71.4MSTROMAL REGULATION OF BASAL CELL CARCINOMA FORMATIONR01AR046786 · NIAMS · STANFORD UNIVERSITY · PI Anthony E Oro · 2001 to 2026
$9.5MPostgraduate Training Program in Epithelial BiologyT32AR007422 · NIAMS · STANFORD UNIVERSITY · PI PAUL KHAVARI · 1986 to 2026
$5.0MREGULATING GLI FUNCTION IN HAIR FOLLICLE PROGENITORSR01AR054780 · NIAMS · STANFORD UNIVERSITY · PI ORO, ANTHONY E · 2007 to 2017
$4.3MRegulating Gli Function in Hair Follicle ProgenitorsR37AR054780 · NIAMS · STANFORD UNIVERSITY · PI Anthony E Oro · 2019 to 2026
$3.7M4DN Interrogation of T Cell Exhaustion in CancerU01CA260852 · NCI · STANFORD UNIVERSITY · PI SATPATHY, ANSUMAN · 2020 to 2024
$2.6MRole of Oncogenic RAS in Multiple Myeloma Disease ProgressionK08CA218893 · NCI · JOHNS HOPKINS UNIVERSITY · PI GOCKE, CHRISTIAN B · 2018 to 2022
$1.1MFour Laser, 18 Color Cell Sorter in the SSFFS10RR025518 · NCRR · STANFORD UNIVERSITY · PI HERZENBERG, LEONARD A · 2009 to 2009
$500kNikon A1Rsi resonant spectral confocal microscopeS10OD010580 · OD · STANFORD UNIVERSITY · PI FULLER, MARGARET T · 2013 to 2013
$377kBD Canto II RUO CytometerS10RR027431 · NCRR · STANFORD UNIVERSITY · PI NOLAN, GARRY P · 2010 to 2010
$236kMolecular pathways associated with BCC to SCC pathway switchingF32CA254434 · NCI · STANFORD UNIVERSITY · PI HAENSEL, DANIEL WILLIAM · 2020 to 2022
$142kDefining the Dynamic Epigenetic Landscape During Epithelial CommitmentF32AR070565 · NIAMS · STANFORD UNIVERSITY · PI PATTISON, JILLIAN M. · 2016 to 2017
$105kNCI NIH HHS F32 CA254434NCI NIH HHS K08 CA218893NCI NIH HHS P30 CA124435NCI NIH HHS U01 CA260852NCRR NIH HHS S10 RR025518NCRR NIH HHS S10 RR027431NIAMS NIH HHS F32 AR070565NIAMS NIH HHS R01 AR046786NIAMS NIH HHS R01 AR054780NIAMS NIH HHS R37 AR054780NIAMS NIH HHS T32 AR007422NIH HHS S10 OD010580
Abstract
Cancer immunotherapies have revolutionized treatment but have shown limited success as single-agent therapies highlighting the need to understand the origin, assembly, and dynamics of heterogeneous tumor immune niches. Here, we use single-cell and imaging-based spatial analysis to elucidate three microenvironmental neighborhoods surrounding the heterogeneous basal cell carcinoma tumor epithelia. Within the highly proliferative neighborhood, we find that TREM2
Indexed as
Basal Cell CarcinomaSkin NeoplasmsCarcinogenesisHumansMacrophagesMembrane GlycoproteinsMonocytesReceptors, ImmunologicSignal TransductionMembrane GlycoproteinsReceptors, ImmunologicTREM2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.